US 11,918,584 B2
Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
James Russell Lipford, Thousand Oaks, CA (US); Jude Robert Canon, Newbury Park, CA (US); Anne Y. Saiki, Moorpark, CA (US); and Karen Louise Rex, Thousand Oaks, CA (US)
Assigned to Amgen Inc., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on Jul. 21, 2022, as Appl. No. 17/870,573.
Application 17/870,573 is a continuation of application No. 16/687,563, filed on Nov. 18, 2019, granted, now 11,439,645.
Claims priority of provisional application 62/865,819, filed on Jun. 24, 2019.
Claims priority of provisional application 62/821,376, filed on Mar. 20, 2019.
Claims priority of provisional application 62/769,355, filed on Nov. 19, 2018.
Prior Publication US 2023/0121955 A1, Apr. 20, 2023
Int. Cl. A61K 31/519 (2006.01); A61K 31/498 (2006.01); A61K 31/506 (2006.01); A61K 31/555 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/519 (2013.01) [A61P 35/00 (2018.01); A61K 31/555 (2013.01); C07K 16/2818 (2013.01)] 31 Claims
 
1. A method of treating cancer mediated by a KRAS G12C mutation in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of (1M)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2 S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyri do[2,3-d]pyrimidin-2(1H)-one, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a SHP2 inhibitor, wherein the cancer is non-small cell lung cancer, small intestine cancer, appendix cancer, colorectal cancer, endometrial cancer, pancreatic cancer, skin cancer, gastric cancer, nasal cavity cancer, or bile duct cancer.